Becton, Dickinson and Co. (BDX)

pos +0.00
Today's Range: 114.99 - 116.75 | BDX Avg Daily Volume: 0
Last Update: 08/01/14 - 4:02 PM EDT
Volume: 0
YTD Performance: 0.00%
Open: $0.00
Previous Close: $116.24
52 Week Range: $96.73 - $120.66
Oustanding Shares: 193,204,000
Market Cap: 22,427,120,300
6-Month Chart
TheStreet Ratings Grade for BDX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy
Moderate Buy
Moderate Sell
Strong Sell
Mean Rec. 0.00 0.00 0.00 0.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
BDX Sector Avg. S&P 500
0.00 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
Revenue 0.00 0.00 0.00
Net Income 0.00 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for BDX:
Revenue 0.00B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (09/14) FY (09/15)
Average Estimate $1.67 $1.56 $6.24 $6.82
Number of Analysts 12 6 2 15
High Estimate $1.69 $1.59 $6.25 $6.90
Low Estimate $1.65 $1.50 $6.23 $6.75
Prior Year $1.58 $1.42 $5.95 $6.24
Growth Rate (Year over Year) 5.85% 9.62% 4.87% 9.23%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Jim Cramer

 | Jul 7, 2014 | 11:18 AM EDT

A wave of M&A in the health sector makes sense.


Jim Cramer

 | Jun 9, 2014 | 6:50 AM EDT

If you step out of the blinding spotlight, the truly rewarding buying opportunities become obvious.

bullishBoston Scientific upgraded at Piper

Jan 21, 2014 | 8:14 AM EST

BSX was upgraded to Overweight, Piper Jaffray said. $18 price target. Company is in the second leg of a multi-year move. 

bullishBecton Dickinson upgraded at BofA/Merrill

Jan 7, 2014 | 8:41 AM EST

BDX was upgraded to Neutral, Bank of America/Merrill Lynch said. $117 price target. Sales and earnings growth should stabilize.

bullishBecton Dickinson upgraded at Piper

Sep 18, 2013 | 7:55 AM EDT

BDX was upgraded from Neutral to Overweight, Piper Jaffray said. $117 price target. Microbiology market should drive earnings growth. 


Robert Moreno

 | Sep 5, 2013 | 2:00 PM EDT

Three charts forming around their 50-day moving average.


John Dorfman

 | Apr 26, 2013 | 12:00 PM EDT

Outperformance by safe sectors often signals trouble, but not always.

updateBDX Investor Mtg.

Jan 29, 2013 | 6:19 AM EST

 BD Annual Shareholder Meeting - 1PM


David Peltier

 | Dec 19, 2012 | 11:41 AM EST

Portfolio Mgr. David Peltier uncovers a low-dollar healthcare stock with big growth potential.


Paul Price

 | Nov 20, 2012 | 12:00 PM EST

This high-quality name seems ready for another sizable climb.

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Bef...
Last year saw the MC NYSE oscillator hit -300 on about five occasions, and each time a mas...
If you are in the NYC area, Bob Lang and I will be in town this Monday and Tuesday night. ...
There are no signals in IWM....Still watching zone 2 in WYNN for a potential entry. The up...


Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.